Evidence map›Paper›PMID 40546137›Full record

ArticleJournal of cachexia, sarcopenia and muscle2025

Ablation of LAT2 Transporter Causes Intramuscular Glutamine Accumulation and Inhibition of Fasting-Induced Proteolysis.

Meritxell Espino-Guarch, Susie Shih Yin Huang, Clara Vilches, Esther Prat, Rana El Nahas, Ghalia Missous, Susanna Bodoy, Abbirami Sathappan, Mohammad Ameen Al-Aghbar, Clara Mayayo and 7 more

Erratum issuedAbstract read
In one paragraph

Article in Journal of cachexia, sarcopenia and muscle, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Trial
  2. Article
  3. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

17 authors.

Meritxell Espino-GuarchLaboratory of Immunoregulation, Research Department, Sidra Medicine, Doha, Qatar.ORCID 0000-0002-7211-3229
Susie Shih Yin HuangLaboratory of Immunoregulation, Research Department, Sidra Medicine, Doha, Qatar.
Clara VilchesGenes, Disease and Therapy Program, Human Molecular Genetics Laboratory - Institut Investigació Biomèdica de Bellvitge (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain.
Esther PratGenes, Disease and Therapy Program, Human Molecular Genetics Laboratory - Institut Investigació Biomèdica de Bellvitge (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain.
Rana El NahasLaboratory of Immunoregulation, Research Department, Sidra Medicine, Doha, Qatar.
Ghalia MissousLaboratory of Immunoregulation, Research Department, Sidra Medicine, Doha, Qatar.
Susanna BodoyInstitute for Research in Biomedicine (IRB Barcelona), The Barcelona Institute of Science and Technology (BIST), Barcelona, Spain.
Abbirami SathappanAdvanced Imaging Core Facility, Sidra Medicine, Doha, Qatar.
Mohammad Ameen Al-AghbarLaboratory of Immunoregulation, Research Department, Sidra Medicine, Doha, Qatar.
Clara MayayoGenes, Disease and Therapy Program, Human Molecular Genetics Laboratory - Institut Investigació Biomèdica de Bellvitge (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain.
Montse OlivéNeuromuscular Disorders Unit, Neurology Department, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.
Silvia Busquets-RiusCancer Research Group, Departament de Bioquimica I Biomedicina Molecular, Facultat de Biologia, Universitat de Barcelona, Barcelona, Spain.
David SebastiánDepartment of Biochemistry and Physiology, School of Pharmacy, University of Barcelona, Barcelona, Spain.
Antonio ZorzanoCentro de Investigación Biomédica en Red de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM).
Manuel PalacinInstitute for Research in Biomedicine (IRB Barcelona), The Barcelona Institute of Science and Technology (BIST), Barcelona, Spain.
Nicholas van PanhuysLaboratory of Immunoregulation, Research Department, Sidra Medicine, Doha, Qatar.
Virginia NunesGenes, Disease and Therapy Program, Human Molecular Genetics Laboratory - Institut Investigació Biomèdica de Bellvitge (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain.

Funding

Qatar National Research Fund NPRP11S-0122-180359Spanish Ministry of Science and Innovation PID2021-122802OB-100Spanish Ministry of Science and Innovation RTI2018-094211-B-100
6 · The paper itself

Abstract

backgroundThe neutral amino acid transporter SLC7A8 (LAT2) has been described as a key regulator of metabolic adaptation. LAT2 mutations in human populations have been linked to the early onset of age-related hearing loss and cataract growth. As LAT2 was previously found to be highly expressed in skeletal muscle, here we characterised its role in the regulation of skeletal muscle amino acid flux and metabolic adaptation to fasting.

methodsWild-type (WT) and LAT2 knock-out (LAT2KO) mice were exposed to short- and long-periods of fasting (16 and 48 h). The impact of the absence of LAT2 on amino acid content, gene expression, proteolysis activity, muscle tone, and histology was measured. To characterise the impact on muscle degradation, we tested LAT2 KO mice in cancer-associated cachexia, streptozocin-induced Type-1 diabetes, and ageing models.

resultsLAT2KO mice experienced a notable reduction in body weight during fasting (WT:14% and LAT2KO:18%, p = 0.02), with a greater reduction in fat mass (0.5-fold, p = 0.013) and a higher relative retention of muscle mass (1.3-fold, p = 0.0003) compared with WT. The absence of LAT2 led to increased intramuscular glutamine (Gln) accumulation (6.3-fold, p < 0.0001), accompanied by a reduction in skeletal muscle proteolysis during fasting (0.61-fold, p = 0.0004) primarily due to decreased proteasomal and autophagic activity (0.45-fold, p = 0.016 and 0.7-fold, p = 0.002, respectively). Ex vivo incubation of LAT2KO muscle with rapamycin recovered proteolysis function, demonstrating a mTORC1-dependent pathway. Decreased proteolysis in LAT2KO animals was associated with increased mTORC1 translocation to the lysosome (mTORC1-Lamp1 colocalization in fasted LAT2KO muscles was 1.23-fold, p < 0.0001). Of the three muscle loss models tested, differences were observed only during ageing. Young LAT2KO mice (3 M) exhibited muscle tone and MurF1 expression levels comparable to those of older WT mice (12 M) (0.44-fold, p = 0.02 and 0.48-fold, p = 0.04, respectively).

conclusionLAT2 has a critical role in regulating Gln efflux from skeletal muscle. The absence of LAT2 led to elevated intracellular Gln levels, impairing muscle proteolysis by inducing mTORC1 recruitment to the lysosome. Further, chronic Gln accumulation and decreased proteolysis were found to induce the early onset of an age-related muscle phenotype.

Indexed as

Amino Acid Transport System y+FastingGlutamineMuscle, SkeletalAnimalsDisease Models, AnimalFusion Regulatory Protein 1, Light ChainsMiceMice, KnockoutProteolysisAmino Acid Transport System y+Fusion Regulatory Protein 1, Light ChainsGlutamineSLC7A8 protein, mouseageingglutamineLAT2mTORC1proteolysisskeletal muscle

Identifiers

PMID40546137
PMCPMC12183528

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.